Zoladex (ICI 118,630): Clinical trial of new luteinizing hormone-releasing hormone analog in metastatic prostatic carcinoma
Authors:
- G.P. MurphyGMG.P. Murphy
- J.M. GrecoJGJ.M. Greco
- J.L. ChinJCJ.L. Chin
- R.P. HubenRHR.P. Huben
- M. ScottMSM. Scott
- H.A. DehaanHDH.A. Dehaan
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Early tumor exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone.BMJ, 1985
- Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer.BMJ, 1985
- Diagnostic and therapeutic uses of gonadotropin-releasing hormoneArchives of internal medicine (1960), 1985
- Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.BMJ, 1985
- Leuprolide versus Diethylstilbestrol for Metastatic Prostate CancerNew England Journal of Medicine, 1984
- Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone.BMJ, 1984
- DISEASE FLARE INDUCED BY LUTEINISING HORMONE RELEASING HORMONE ANALOGUES IN CANCER PATIENTSThe Lancet, 1984
- Use of estramustine phosphate in prostate cancer by the National Prostatic Cancer Project and by Roswell Park Memorial InstituteUrology, 1984
- Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist.BMJ, 1983
- ENDOCRINE CONTROL OF PROSTATIC CARCINOMAJAMA, 1950